Download PDF
Thromb Haemost 2017; 117(01): 196-197
DOI: 10.1160/TH16-06-0445
Letters to the Editor
Schattauer GmbH

Idarucizumab administration for reversing dabigatran effect in an acute kidney injured patient with bleeding

Hervé Quintard
1   Intensive Care Unit, Pasteur Hospital, CHU Nice, Nice, France
,
Delphine Viard
2   Department of Pharmacy, Pasteur Hospital, CHU Nice, Nice, France
,
Milou-Daniel Drici
3   Department of Pharmacovigilance, Pasteur Hospital, CHU Nice, Nice, France
,
Caroline Ruetsch
4   Department of Haematology, Archet Hospital, CHU Nice, Nice, France
,
Charles Marc Samama
5   Department of Anesthesiology and Intensive Care, Cochin University Hospital, Assistance Publique des Hopitaux de Paris, Université Paris Descartes, Paris, France
,
Carole Ichai
1   Intensive Care Unit, Pasteur Hospital, CHU Nice, Nice, France
› Author Affiliations
Further Information

Publication History

Received: 10 June 2016

Accepted after major revision: 20 September 2016

Publication Date:
01 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Alberts MJ, Bernstein RA, Naccarelli GV, Garcia DA. Using dabigatran in patients with stroke: a practical guide for clinicians. Stroke 2012; 43: 271-279.
    CrossrefPubMedGoogle Scholar
  • 2 Fu W, Guo H, Guo J. et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis. J Cardiovasc Med 2014; 15: 873-879.
    CrossrefPubMedGoogle Scholar
  • 3 Connolly SJ, Ezekowitz MD, Yusuf S. et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
    CrossrefPubMedGoogle Scholar
  • 4 Miyares MA, Kuyumjian Y, Eaves S, Dollard E. Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran. J Pharm Pract 2015; 28: 548-554.
    CrossrefPubMedGoogle Scholar
  • 5 Glund S, Stangier J, Schmohl M. et al. Safety, tolerability, and efficacy of Idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015; 386: 680-690.
    CrossrefPubMedGoogle Scholar
  • 6 Glund S, Moschetti V, Norris S. et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of Idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113: 943-951.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Pollack CV, Reilly PA, Eikelboom J. et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-520.
    CrossrefPubMedGoogle Scholar